| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Josef T Prchal | |
| Neeraj Agarwal | |||
| P2860 | cites work | The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 |
| HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing | Q24291102 | ||
| RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia | Q24298480 | ||
| Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension | Q24307473 | ||
| A gain-of-function mutation in the HIF2A gene in familial erythrocytosis | Q24654396 | ||
| Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex | Q24654714 | ||
| HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques | Q24684076 | ||
| Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation | Q27860876 | ||
| Efficacy and safety of epoetin alfa in critically ill patients | Q28246281 | ||
| Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells | Q28282130 | ||
| Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency | Q28297161 | ||
| Acute postnatal ablation of Hif-2alpha results in anemia | Q28591898 | ||
| Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo | Q28594830 | ||
| Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients | Q33243661 | ||
| Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression | Q33288270 | ||
| Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study | Q33326646 | ||
| Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells | Q33730124 | ||
| Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades | Q34086191 | ||
| Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia | Q34157665 | ||
| HIF-1 and mechanisms of hypoxia sensing | Q34180645 | ||
| Pharmacologically regulated cell therapy | Q34225667 | ||
| Controlling Signal Transduction with Synthetic Ligands | Q34306937 | ||
| Erythropoietin and the nervous system | Q34309805 | ||
| Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. | Q34529820 | ||
| Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise | Q34567935 | ||
| A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics | Q35075541 | ||
| Expression cloning of the murine erythropoietin receptor | Q35416452 | ||
| Erythropoietin both protects from and reverses experimental diabetic neuropathy | Q35554405 | ||
| Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy | Q35696941 | ||
| Growth factor receptors as regulators of hematopoiesis | Q35848814 | ||
| A novel protective effect of erythropoietin in the infarcted heart | Q36001255 | ||
| Erythropoietin therapy for acute stroke is both safe and beneficial | Q36088111 | ||
| The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations | Q36204170 | ||
| CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. | Q36289609 | ||
| Regulation of angiogenesis by hypoxia-inducible factor 1. | Q36485190 | ||
| Erythropoietin in cancer: presumption of innocence? | Q36803489 | ||
| Risks and benefits of erythropoiesis-stimulating agents in cancer management | Q36881654 | ||
| Erythropoietin and treatment of non-anemic conditions--cardiovascular protection | Q36881667 | ||
| Novel erythropoiesis-stimulating agents: a new era in anemia management | Q37031261 | ||
| Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease | Q37072955 | ||
| Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia | Q37100060 | ||
| The non-haematopoietic biological effects of erythropoietin | Q37103957 | ||
| Types of anemia and mortality among older disabled women living in the community: the Women's Health and Aging Study I. | Q37118171 | ||
| Calcineurin promotes hypoxia-inducible factor 1alpha expression by dephosphorylating RACK1 and blocking RACK1 dimerization | Q37125538 | ||
| Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor | Q37571920 | ||
| Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin | Q38294090 | ||
| Human, rat, and mouse kidney cells express functional erythropoietin receptors | Q38327858 | ||
| Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis | Q38333334 | ||
| Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease | Q38337379 | ||
| Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin | Q38355642 | ||
| Serum erythropoietin and aging: a longitudinal analysis | Q38441591 | ||
| Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. | Q39552802 | ||
| CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice | Q40017689 | ||
| The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease | Q40092893 | ||
| Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients | Q40173236 | ||
| Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. | Q40230680 | ||
| Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. | Q41055727 | ||
| Inactivation of erythropoietin leads to defects in cardiac morphogenesis | Q41679719 | ||
| Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors | Q42455621 | ||
| Erythropoietin expression in primary rat Sertoli and peritubular myoid cells | Q42511877 | ||
| Anemia in the elderly: a public health crisis in hematology | Q42673911 | ||
| Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture | Q43577442 | ||
| Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia | Q43611163 | ||
| Impact of anemia on mortality, cognition, and function in community-dwelling elderly | Q44030916 | ||
| Pharmacologically regulated in vivo selection in a large animal | Q44117631 | ||
| Anemia is associated with disability and decreased physical performance and muscle strength in the elderly | Q44846134 | ||
| Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia | Q44967334 | ||
| Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure | Q45012602 | ||
| Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy | Q46667958 | ||
| Anatomical compartments modify the response of human hematopoietic cells to a mitogenic signal | Q46864865 | ||
| Hemoglobin levels and skeletal muscle: results from the InCHIANTI study | Q47925051 | ||
| Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation | Q48119740 | ||
| The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. | Q48421828 | ||
| Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage | Q48617513 | ||
| Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). | Q50672978 | ||
| Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. | Q50685607 | ||
| Economic burden of patients with anemia in selected diseases. | Q50772464 | ||
| Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. | Q51694824 | ||
| Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. | Q52202995 | ||
| Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis | Q59264385 | ||
| Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly | Q61428121 | ||
| Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization | Q61965065 | ||
| Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization | Q68255477 | ||
| On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action | Q68695500 | ||
| Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes | Q69323711 | ||
| Localization of cells producing erythropoietin in murine liver by in situ hybridization | Q70167724 | ||
| Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production | Q70482972 | ||
| Familial Polycythemia | Q71855263 | ||
| Origin and fate of erythropoietin in human milk | Q73108880 | ||
| The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin | Q77153488 | ||
| Correction of anemia with epoetin alfa in chronic kidney disease | Q79363020 | ||
| Are erythropoietin receptors expressed in tumors? Facts and fiction--more careful studies are needed | Q80242639 | ||
| Does erythropoietin promote tumor growth? | Q80889046 | ||
| Anti-Epo receptor antibodies do not predict Epo receptor expression | Q81402534 | ||
| Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration | Q81503582 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 267-275 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Seminars in Hematology | Q15765535 |
| P1476 | title | Erythropoietic agents and the elderly | |
| P478 | volume | 45 |
| Q40825620 | Integrity of the prolyl hydroxylase domain protein 2:erythropoietin pathway in aging mice |
| Q36317698 | Management of anemia of inflammation in the elderly |
| Q58793895 | Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts |
| Q35631773 | Not so benign haematology: anaemia of the elderly |
Search more.